礼来(LLY.US)“塞普替尼片”在中国获批上市

智通财经
Yesterday
【礼来(LLY.US)“塞普替尼片”在中国获批上市】智通财经APP获悉,9月18日,NMPA官网显示,礼来制药(LLY.US) 5.1 类新药“塞普替尼片”在国内获批上市。公开资料显示,这是塞普替尼片剂剂型首次在国内获批。塞普替尼(Selpercatinib)是一种同类首创,高选择性和抑制活性的小分子 RET 抑制剂,具有中枢神经系统(CNS)活性,可抑制多种RET变异。该药是全球首款获批的高选择性 RET 抑制剂,通过抑制异常 RET 激酶的活性而发挥作用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10